Next 10 |
2024-05-15 10:42:04 ET More on AN2 Therapeutics Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference AN2 Therapeutics reports FY results Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics ...
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-04-23 11:37:17 ET Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from ...
2024-04-22 16:53:54 ET Gainers: Oportun Financial ( OPRT ) +5% . Humacyte ( HUMA ) +2% . Revance Therapeutics ( RVNC ) +2% . Office Properties Income ( OPI ) +2% . Axcelis Technologies ( ACLS ) +1% . Losers: C...
2024-04-02 05:30:04 ET JMP Securities analyst issues OUTPERFORM recommendation for ANTX on April 2, 2024 02:23AM ET. ANTX was trading at $3.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recom...
2024-03-29 06:57:13 ET More on AN2 Therapeutics Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference AN2 Therapeutics reports FY results AN2 Therapeutics extends losses as Leerink cuts on trial setback Seeking Alpha’s Quant Rating on A...
2024-03-28 17:11:08 ET More on AN2 Therapeutics Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference AN2 Therapeutics extends losses as Leerink cuts on trial setback Biggest stock movers today: Diamondback Energy, Joby Aviation, monday.com, and more ...
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and inve...
2024-03-15 15:16:36 ET More on the markets Fairlead Strategies founder: This year is the year of the long-term turnarounds Inflation Is Not Running Hot S&P 500: Stay Invested, Cut Risk, And Be Ready To Buy The Dips The next Nvidia? Goldman Sachs spotlight...
News, Short Squeeze, Breakout and More Instantly...
AN2 Therapeutics Inc. Company Name:
ANTX Stock Symbol:
NYSE Market:
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-04-02 05:30:04 ET JMP Securities analyst issues OUTPERFORM recommendation for ANTX on April 2, 2024 02:23AM ET. ANTX was trading at $3.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recom...